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Jefferson and colleagues say that nebulisation is the route of administration for zanamivir.[@ref1] However, prescribers should be aware that the approved use of zanamivir in the United States and European Union is by inhalation, not nebulisation.[@ref2] [@ref3]

The Food and Drug Administration recently issued a warning against using the inhalation formulation in a solubilised form for nebulised delivery,[@ref4] and letters have been sent to prescribers in the US proscribing the use of zanamivir by the nebulised route because of a reported death after administration this way.[@ref5]
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